Evidence map›Paper›PMID 42300696›Full record

ArticleJournal of Alzheimer's disease : JAD2026

Plasma p-tau217 measured by the Elecsys automated immunoassay: Prospective validation in a heterogeneous memory clinic cohort.

Emilio Franco-Macías, José Ángel Noval-Padillo, Rocío Hervás-Navidad, Beatriz Espejo-Martínez, Cristina Serrano-Gutiérrez, Silvia Rodrigo-Herrero, Carlota Méndez-Barrio, Gonzalo Mendoza-Vázquez, Ismael Carrera-Muñoz, Bartolomé Marín-Romero and 22 more

Abstract readValidation Study
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Emilio Franco-MacíasMemory Unit, Department of Neurology, Virgen del Rocío University Hospital, Seville, Spain.ORCID 0000-0003-4186-1037
José Ángel Noval-PadilloClinical Biochemistry Department, Virgen del Rocío University Hospital, Seville, Spain.
Rocío Hervás-NavidadAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.
Beatriz Espejo-MartínezAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.
Cristina Serrano-GutiérrezAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.
Silvia Rodrigo-HerreroAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.ORCID 0000-0002-7784-272X
Carlota Méndez-BarrioAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.
Gonzalo Mendoza-VázquezAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.ORCID 0000-0003-1091-3412
Ismael Carrera-MuñozAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.
Bartolomé Marín-RomeroAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.
Francisco Garzón-MaldonadoAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.
Lina Carazo-BarriosAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.
Lucía Rodríguez-JiménezAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.
Ángel Martínez-NoguerasAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.
Eduardo Agüera-MoralesAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.ORCID 0000-0002-8604-2054
Cristina Conde-GavilánAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.
Ana María JoverAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.
Carmen García-NavarroAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.ORCID 0000-0002-9582-0989
Mar Iglesias-EspinosaAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.ORCID 0000-0002-2314-7211
David José Romera-MoralesAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.
Eva Cuartero-RodríguezAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.
Ernesto García-RoldánMemory Unit, Department of Neurology, Virgen del Rocío University Hospital, Seville, Spain.ORCID 0000-0002-4826-262X
Melisa González-AcostaMethodological and Statistical Support Unit, Fundación para la Gestión de la Investigación en Salud de Sevilla (FISEVI), Seville, Spain.ORCID 0009-0001-5922-5306
Ángela Almodóvar-SierraMemory Unit, Department of Neurology, Virgen del Rocío University Hospital, Seville, Spain.
Marta Marín-CabañasMemory Unit, Department of Neurology, Virgen del Rocío University Hospital, Seville, Spain.
María Bernal Sánchez-ArjonaMemory Unit, Department of Neurology, Virgen del Rocío University Hospital, Seville, Spain.
María Isabel García-SánchezBiobank of the Andalusian Public Health System, Seville, Spain.ORCID 0000-0003-4098-7738
José Enrique Arriola-InfanteMemory Unit, Department of Neurology, Torrécardenas University Hospital, Almería, Spain.ORCID 0000-0002-3298-4601
Carlos Arrabal-GómezAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.
Begoña Oliver-MartosBiomedical Research Institute and the Nanomedicine Platform-IBIMA BIONAND Platform, Málaga, Spain.
Pedro Jesús Serrano-CastroAndalusia-NEURO-RECA/Roche Alliance in Precision Neurological Medicine, Spain.ORCID 0000-0002-3414-2707
Daniel Fatela-CantilloClinical Biochemistry Department, Virgen del Rocío University Hospital, Seville, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundPlasma phosphorylated tau at threonine 217 (p-tau217) has emerged as a leading blood-based biomarker for the diagnosis of Alzheimer's disease (AD) and can be measured using fully automated, random-access platforms. The Elecsys plasma p-tau217 assay requires further validation, particularly in heterogenous populations seen in memory clinics.ObjectiveTo validate plasma p-tau217 in comparison with p-tau181 and to evaluate its association with other soluble core 1 AD biomarkers, as well as markers of neurodegeneration and neuroinflammation.MethodsBiobank data from two prospective blood-based biomarkers validation studies were analyzed. Cerebrospinal fluid (CSF) p-tau181/Aβ

Indexed as

Alzheimer Diseasetau ProteinsAgedAmyloid beta-PeptidesBiomarkersCohort StudiesFemaleGlial Fibrillary Acidic ProteinHumansImmunoassayMaleMiddle AgedPeptide FragmentsPhosphorylationProspective StudiesAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersGlial Fibrillary Acidic ProteinMAPT protein, humanPeptide Fragmentstau ProteinsAlzheimer's diseasebiomarkersblood biomarkerslaboratory techniques/procedures

Identifiers

PMID42300696
PMCPMC13392156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.